Ravagalimab (ABBV-323) is a CD40 antagonist monoclonal antibody with an EC50 of 3.7 nM. Ravagalimab is being investigated for the treatment of inflammatory diseases such as Crohns disease and Sjögrens syndrome (SS). Research focuses on evaluating its pharmacological activity, efficacy, and safety in patients with primary Sjögrens syndrome (pSS), highlighting its role in immune modulation.
Purity:
95.00%
CAS Number:
[2050816-56-1]
Target:
TNF
* VAT and and shipping costs not included. Errors and price changes excepted